See more : BrightSphere Investment Group Inc. (BSIG) Income Statement Analysis – Financial Results
Complete financial analysis of Daewon Pharmaceutical Co., Ltd. (003220.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Daewon Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Laredo Oil, Inc. (LRDC) Income Statement Analysis – Financial Results
- PT XL Axiata Tbk (PTXKY) Income Statement Analysis – Financial Results
- Zions Bancorporation, National Association (ZION) Income Statement Analysis – Financial Results
- Q-Free ASA (QFREF) Income Statement Analysis – Financial Results
- E Lighting Group Holdings Limited (8222.HK) Income Statement Analysis – Financial Results
Daewon Pharmaceutical Co., Ltd. (003220.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.daewonpharm.com
About Daewon Pharmaceutical Co., Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 526.95B | 478.88B | 354.18B | 308.50B | 317.83B | 286.65B | 265.46B | 240.72B | 216.19B | 181.98B | 158.88B | 138.17B | 138.87B | 144.70B | 115.93B | 90.66B | 74.36B |
| Cost of Revenue | 272.72B | 240.94B | 177.71B | 142.56B | 137.67B | 121.16B | 113.42B | 103.21B | 99.04B | 81.68B | 73.87B | 65.62B | 61.65B | 58.34B | 44.44B | 30.85B | 24.18B |
| Gross Profit | 254.23B | 237.94B | 176.47B | 165.94B | 180.16B | 165.49B | 152.04B | 137.51B | 117.15B | 100.30B | 85.01B | 72.55B | 77.22B | 86.36B | 71.49B | 59.81B | 50.18B |
| Gross Profit Ratio | 48.25% | 49.69% | 49.82% | 53.79% | 56.68% | 57.73% | 57.28% | 57.13% | 54.19% | 55.12% | 53.51% | 52.51% | 55.61% | 59.68% | 61.67% | 65.98% | 67.48% |
| Research & Development | 18.21B | 19.47B | 24.56B | 13.48B | 10.24B | 9.28B | 6.76B | 6.63B | 6.44B | 10.04B | 5.75B | 4.79B | 5.68B | 2.21B | 1.99B | 1.52B | 1.92B |
| General & Administrative | 31.43B | 41.34B | 27.67B | 20.33B | 21.74B | 20.90B | 22.10B | 19.12B | 17.27B | 13.25B | 11.52B | 9.51B | 9.13B | 9.10B | 9.18B | 7.84B | 6.67B |
| Selling & Marketing | 72.01B | 58.27B | 50.86B | 45.13B | 46.66B | 43.62B | 40.06B | 26.91B | 22.13B | 15.50B | 12.42B | 9.55B | 13.70B | 21.61B | 18.15B | 16.29B | 12.72B |
| SG&A | 203.79B | 99.62B | 78.53B | 65.45B | 68.39B | 64.52B | 62.16B | 46.04B | 39.39B | 28.74B | 23.93B | 19.06B | 22.83B | 30.71B | 27.33B | 24.13B | 19.39B |
| Other Expenses | 0.00 | 95.32B | 78.51B | 62.91B | 66.41B | 1.29B | -578.29M | -109.65M | -52.03M | 2.78B | 161.35M | 207.31M | -185.70M | -1.49B | -1.19B | -807.81M | -699.11M |
| Operating Expenses | 222.00B | 194.94B | 157.04B | 141.84B | 145.05B | 134.74B | 126.75B | 108.37B | 94.07B | 82.50B | 69.47B | 59.05B | 63.84B | 66.29B | 57.43B | 48.25B | 40.63B |
| Cost & Expenses | 494.72B | 435.88B | 334.75B | 284.40B | 282.72B | 255.91B | 240.17B | 211.57B | 193.10B | 164.18B | 143.33B | 124.67B | 125.49B | 124.63B | 101.87B | 79.10B | 64.81B |
| Interest Income | 1.28B | 1.12B | 270.52M | 160.55M | 237.83M | 234.92M | 224.41M | 226.92M | 417.58M | 739.65M | 749.60M | 690.25M | 351.57M | 539.43M | 494.62M | 628.64M | 650.26M |
| Interest Expense | 4.61B | 3.68B | 2.08B | 1.18B | 268.57M | 89.41M | 150.64M | 0.00 | 26.24M | 100.46M | 126.10M | 226.51M | 285.64M | 368.11M | 288.16M | 399.95M | 98.30M |
| Depreciation & Amortization | 17.56B | 19.37B | 17.81B | 15.67B | 11.88B | 10.40B | 8.70B | 7.47B | 5.98B | 4.33B | 4.04B | 3.78B | 3.45B | 4.28B | 4.14B | 2.35B | 2.22B |
| EBITDA | 47.50B | 62.27B | 37.11B | 39.65B | 47.44B | 40.99B | 33.90B | 36.62B | 28.78B | 22.13B | 19.59B | 16.56B | 16.26B | 24.85B | 16.78B | 12.53B | 11.99B |
| EBITDA Ratio | 9.01% | 13.62% | 11.19% | 13.30% | 15.04% | 14.90% | 12.70% | 15.93% | 13.67% | 14.17% | 13.00% | 13.08% | 12.29% | 16.22% | 15.29% | 15.38% | 15.83% |
| Operating Income | 32.23B | 43.01B | 19.43B | 24.10B | 35.11B | 30.75B | 25.29B | 29.15B | 23.09B | 17.81B | 15.54B | 13.50B | 12.67B | 20.07B | 14.06B | 11.56B | 9.55B |
| Operating Income Ratio | 6.12% | 8.98% | 5.48% | 7.81% | 11.05% | 10.73% | 9.53% | 12.11% | 10.68% | 9.78% | 9.78% | 9.77% | 9.12% | 13.87% | 12.13% | 12.75% | 12.84% |
| Total Other Income/Expenses | -6.40B | -4.28B | -2.29B | -457.39M | 265.11M | -2.59B | -1.77B | -1.40B | -1.94B | 3.32B | 57.85M | -942.89M | -852.54M | 130.61M | -1.71B | -1.78B | 124.69M |
| Income Before Tax | 25.83B | 38.72B | 17.14B | 23.64B | 35.37B | 31.21B | 23.52B | 27.75B | 23.25B | 21.12B | 15.60B | 12.56B | 12.53B | 20.20B | 12.35B | 9.78B | 9.67B |
| Income Before Tax Ratio | 4.90% | 8.09% | 4.84% | 7.66% | 11.13% | 10.89% | 8.86% | 11.53% | 10.75% | 11.61% | 9.82% | 9.09% | 9.02% | 13.96% | 10.65% | 10.79% | 13.01% |
| Income Tax Expense | 2.37B | 8.06B | 10.53B | 6.44B | 8.49B | 7.92B | 13.25B | 8.03B | 5.91B | 5.53B | 3.37B | 2.79B | 3.27B | 8.35B | 2.59B | 2.11B | 1.85B |
| Net Income | 23.92B | 31.94B | 6.99B | 17.64B | 27.29B | 23.74B | 10.74B | 20.24B | 17.69B | 15.73B | 12.32B | 9.61B | 9.44B | 11.85B | 9.76B | 7.67B | 7.82B |
| Net Income Ratio | 4.54% | 6.67% | 1.97% | 5.72% | 8.59% | 8.28% | 4.05% | 8.41% | 8.19% | 8.64% | 7.75% | 6.96% | 6.79% | 8.19% | 8.42% | 8.46% | 10.52% |
| EPS | 1.14K | 1.51K | 329.36 | 826.31 | 1.27K | 1.10K | 473.96 | 906.62 | 790.24 | 688.52 | 539.35 | 401.93 | 478.70 | 590.61 | 525.51 | 403.52 | 399.41 |
| EPS Diluted | 1.10K | 1.48K | 329.36 | 826.31 | 1.27K | 1.07K | 473.96 | 906.62 | 790.24 | 688.52 | 539.35 | 401.93 | 478.70 | 590.61 | 525.51 | 403.52 | 399.41 |
| Weighted Avg Shares Out | 20.98M | 21.16M | 21.22M | 21.35M | 21.57M | 21.57M | 21.58M | 21.67M | 21.75M | 22.84M | 22.84M | 23.92M | 19.71M | 20.06M | 18.58M | 19.02M | 19.58M |
| Weighted Avg Shares Out (Dil) | 21.66M | 21.88M | 21.22M | 21.35M | 21.57M | 22.22M | 22.66M | 22.33M | 22.39M | 22.84M | 22.84M | 23.92M | 19.71M | 20.06M | 18.58M | 19.02M | 19.58M |
Source: https://incomestatements.info
Category: Stock Reports